Bayer halts vilaprisan drug trials due to toxicology data

Bayer said it halted trials testing its experimental uterine fibroids treatment vilaprisan, which it previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.

from Reuters: Health News https://ift.tt/2G1DapV
via IFTTT